Phillyrin prevents sepsis-induced acute lung injury through inhibiting the NLRP3/caspase-1/GSDMD-dependent pyroptosis signaling pathway
Acute lung injury (ALI) is a severe pulmonary disorder of sepsis with high clinical incidence and mortality. Nucleotide-binding oligomerization domain-like receptor family pyrin domain containing 3 (NLRP3)-cysteinyl aspartate specific proteinase 1-gasdermin D (GSDMD)-dependent pyroptosis of alveolar epithelial cells (AECs) has emerged as a crucial contributor to ALI during sepsis. Phillyrin (PHI), a natural lignan isolated from the traditional Chinese herbal medicine <i>Forsythia suspensa</i>, has been shown to have anti-inflammatory, antioxidant and antiviral properties. However, little is known about the protective role and potential mechanism of PHI in sepsis-induced ALI, and it is uncertain whether the protective effect of PHI in sepsis-induced ALI is connected to pyroptosis. This study aims to examine the preventive effects of PHI on sepsis-induced ALI via the inhibition of NLRP3/caspase-1/GSDMD-mediated pyroptosis in AECs. Our findings demonstrate that preadministration of PHI successfully reduces sepsis-induced pulmonary edema, systemic/pulmonary inflammation, and pulmonary histological damage in lung tissues, bronchoalveolar lavage fluid, and the serum of septic mice. Intriguingly, PHI preadministration suppresses sepsis-induced protein expressions of pyroptosis-specific markers, especially their active forms. <i>In vitro</i> assays show that PHI pretreatment also protects type II AECs (MLE-12) from lipopolysaccharide-induced pyroptosis by preventing the activation of the pyroptosis signaling pathway. The results from molecular docking and surface plasmon resonance reveal that PHI has a significant affinity for direct binding to the GSDMD protein, suggesting that GSDMD is a potential pharmacological target for PHI. In conclusion, PHI can prevent sepsis-triggered ALI by effectively suppressing the activation of the canonical pyroptosis signaling pathway and pyroptosis of AECs.
Authors
- Ketao Ma (ORCID: https://orcid.org/0000-0001-5220-7239)
- Liang Zhang (ORCID: https://orcid.org/0000-0002-2279-2657)
- Ling Li (ORCID: https://orcid.org/0000-0002-2763-0761)
- Ji Chen (ORCID: https://orcid.org/0000-0003-3689-4782)
- Zhiyi Li (ORCID: https://orcid.org/0009-0008-0779-9720)
- Jiaxing Liu (ORCID: https://orcid.org/0000-0001-9691-8470)
- Xiaoyan Hao
- Hanyu Yan
Institutions
- Shihezi University (CN)
- First Affiliated Hospital of Shihezi University Medical College (CN)
Publication Details
- Journal
- Acta Biochimica et Biophysica Sinica
- Published
- 2024-09-06
- DOI
- https://doi.org/10.3724/abbs.2024161
- Citations
- 16
- Primary Topic
- Inflammasome and immune disorders
- Type
- article
- Field-Weighted Citation Impact
- 3.74